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Abstract Statins alone are not always adequate therapy to
achieve low-density lipoprotein (LDL) goals in many
patients. Many options are available either alone or in
combination with statins that makes it possible to reach
recommended goals in a safe and tolerable fashion for most
patients. Ezetimibe and bile acid sequestrants reduce
cholesterol transport to the liver and can be used in
combination. Niacin is very effective at lowering LDL,
beyond its ability to raise high-density lipoprotein and shift
LDL particle size to a less atherogenic type. When statins
cannot be tolerated at all, red yeast rice can be used if
proper formulations of the product are obtained. Nutrients
can also be added to the diet, including plant stanols and
sterols, soy protein, almonds, and fiber, either individually
or all together as a portfolio diet. A clear understanding of
how each of these strategies works is essential for effective
results.
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Introduction
Statin therapy is the most effective way to reduce low-
density lipoprotein (LDL) to target goals, and their
pleiotropic effects are also thought to contribute additional
vasculoprotective benefit. However, often times the LDL
goal cannot be achieved with statins alone. This may occur
because even at the highest dose of the most effective
statin, the ideal LDL is not reached or because, due to
financial constraints, the most effective statin may not be
affordable. It may also occur because patients have
intolerable side effects to what otherwise would be an
effective statin dose or for that matter any statin at all.
Finally, abnormalities in liver or muscle enzymes may limit
their use. These barriers contribute to the fact that only
about 60% of patients at risk are at their LDL target [1].
This article reviews what options are available to help
patients reach their LDL goals when statin therapy is not
enough.
Physiology of Cholesterol Absorption and Metabolism:
Opportunities for Therapy
Cholesterol is an essential structural component of mam-
malian cell membranes, where it is required to establish
proper membrane permeability and is also required for the
manufacture of bile acids, steroid hormones, and Vitamin
D. Adequate stores of cholesterol are vital and achieved
through exogenous sources and endogenous pathways of
cholesterol metabolism [2]. Ingestion of cholesterol and its
active absorption of cholesterol in the gut and enterohepatic
recirculation of bile acids from the gut back to the liver are
referred to as exogenous pathways of cholesterol metabo-
lism. Synthesis of cholesterol within the liver and reverse
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either by the direct or indirect pathways, is considered the
endogenous component of cholesterol metabolism. The
direct pathway utilizes high-density lipoprotein (HDL)
receptors, such as scavenger receptor BI (SR-BI), that
mediate the selective uptake of cholesterol from HDL. The
second mechanism is the indirect one, mediated by
cholesterol ester transfer protein (CETP). This protein
exchanges triglycerides of very low-density lipoprotein
(VLDL) with cholesterol esters of HDL. The VLDL is
then processed to LDL and removed from the circulation by
the LDL receptor pathway. The triglycerides are not stable
in HDL but degraded by hepatic lipase, converting them to
small HDL particles where they are capable of picking up
cholesterol from cells by interaction with the ATP-binding
cassette transporter A1 (ABCA1) and then unloading their
cholesterol content back to the liver by the direct pathway.
Because cholesterol is not water soluble, its transport
through the blood requires it to be carried by water-
soluble lipoproteins. The type of lipoprotein also deter-
mines how the triglycerides and cholesterol within them are
metabolized, and to what organs and tissues in the body
they are delivered. Most notably, apolipoprotein B (apoB)
is the primary apolipoprotein of LDL. It is responsible for
delivering cholesterol to tissues and acts as a ligand for
LDL receptors in various cells throughout the body, thus
allowing the influx of cholesterol into the cells. ApoA-I, on
the other hand, is the major protein component of HDL.
This protein has the exact opposite effect of ApoB and
promotes cholesterol efflux from tissues and reverse
transport to the liver for excretion [3].
Thus, we see that there are numerous targets for therapy
that can be utilized to reduce LDL by affecting either the
exogenous or endogenous pathways of cholesterol metab-
olism or both simultaneously. These include a reduction of
cholesterol in the diet along with medications or nutrients
that reduce the absorption of ingested cholesterol within the
gut or that prevent entero-hepatic recirculation of bile acids.
All these methods will reduce the total cholesterol pool by
affecting the exogenous pathways of cholesterol metabo-
lism. They also work extremely well when used in
combination with strategies that block the endogenous
pathways of cholesterol metabolism, such as statins. When
the cholesterol pool is depleted, the liver can replenish its
supply of cholesterol in two ways. First it can do so by
increasing the activity of HMG-CoA reductase, the rate-
controlling enzyme for the production of cholesterol, and
secondly by absorbing more cholesterol from the blood by
upregulation of LDL receptors. However, if cholesterol
synthesis is blocked by statins then the only way for the
liver to obtain more cholesterol is by further upregulation of
LDL receptors, causing even greater clearance of LDL from
the blood.
This article summarizes how each step of the process of
cholesterol metabolism can be altered in order to achieve
the LDL goal when statins are not enough.
Strategies That Affect Exogenous Cholesterol
Metabolism
Reduction of Fat and Cholesterol in the Diet
It is an accepted principle that a key component of
lowering cholesterol in the blood is diet. Certainly
maintaining an ideal weight and regular exercise is
essential to help prevent the metabolic syndrome and
reduce the likelihood of developing diabetes. However,
the effect on total and LDL cholesterol by limiting
dietary intake of cholesterol and fat in the diet appears
to be relatively small. In a study by Hunninghake et al.
[4] in 1993, 97 patients underwent consecutive 9-week
periods of two different dietary regimens. Each dietary
regimen also included an additional 9 weeks of either
placebo or 20 mg of lovastatin. The dietary regimens were
either a diet high in fat and cholesterol intended to
resemble the average US diet or a National Cholesterol
Education Program (NCEP) step 2 diet. The high fat and
cholesterol diet provided approximately 40% of calories as
fat, with 15% saturated, 14% monounsaturated, and 8%
polyunsaturated fatty acids, and a cholesterol intake of
350 to 400 mg per day. The NCEP step 2 diet consisted of
very low levels of saturated fat (<7%) and cholesterol
(<200 mg). The reduction in the total cholesterol and LDL
between the two diets was only 5% and apoB only
decreased by 2%. For comparison, lovastatin in the high-
fat diet decreased LDL by 27% and in the low-fat diet plus
lovastatin, a further 5%. In another study, 120 patients
were randomized to receive either their “habitual diet” or a
Mediterranean diet for 12 weeks [5]. During those
12 weeks, each group was further randomized to receive
20 mg of simvastatin or placebo. After 12 weeks, the
simvastatin groups were crossed over to receive placebo
for 12 weeks and the placebo groups crossed over to
receive simvastatin for 12 weeks. The Mediterranean diet
consisted of no more than 10% energy from saturated fats
and trans-unsaturated fats, and the cholesterol intake was
l e s st h a n2 5 0m gp e rd a y .I ta l s oi n c l u d e d4gp e rd a yo f
omega-3 fatty acid of plant and marine origin. This diet
also required increased intake of fruit, vegetables, and
soluble fiber. The effect of diet alone on reducing LDL
was about 11%, simvastatin about 30%, and the combi-
nation of both 40%. Thus, even in the patients who are
dietary compliant, reductions of LDL cholesterol may
only be in the 5% to 10% range and usually other
strategies to reach the LDL goal will be required.
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Bile acid sequestrants (BAS) work by blocking one of
the exogenous pathways of cholesterol metabolism,
namely enterohepatic recirculation. About 1,000 mg of
cholesterol daily is secreted into bile and subsequently
into the intestine. These bile acids are essential to
emulsify and solubilize lipids for intestinal absorption.
About 95% of the bile acids secreted into the intestines
are reabsorbed through enterohepatic recirculation. Bile
acid sequestrants bind intestinal bile acids in the gut,
forming insoluble complexes that are then excreted. By
blocking enterohepatic recirculation and depleting the
liver of ready-made bile acids, the liver increases
synthesis of cholesterol and up-regulates LDL receptors
on its surface, which results in increased clearance of
LDL cholesterol from the systemic circulation [6].
Earlier generations of BAS, such as cholestyramine,
have been demonstrated to be effective in lowering total
and LDL cholesterol as well as reducing mortality and
cardiovascular events (7% and 24%, respectively). Howev-
er, they have not been generally well tolerated due to
significant gastrointestinal (GI) side effects, including
abdominal pain, heartburn, bloating, and constipation [7].
A new generation of BAS is currently available and is
more effective and better tolerated than cholestyramine [6].
Colesevelam is a high-capacity bile acid-binding agent and
has been reported to be four to six times more potent than
older BAS and reduces LDL cholesterol in a dose-
dependent manner. In a double-blind study, colesevelam,
at a dose of 4.5 g/d, reduced median LDL cholesterol by
20%, raised HDL cholesterol by 3% to 4% and nonsignif-
icantly raised triglycerides by 5% to 10% [8]. This
compares with a reduction in LDL in the Lipid Research
Clinics Coronary Primary Prevention Trial (LRC) with
cholestyramine of only 12.6% versus placebo. The response
is rapid, and maximal reductions in LDL occur within 2
two weeks of treatment. In addition, although GI side
effects do occur, they are milder and occur less often than
with cholestyramine. This is because colesevelam is a
water-absorbing gel that creates a soft gelatinous material
that may explain its better-tolerated GI side-effect profile.
The overall incidence of GI side effects as compared to
placebo was 4% for constipation, 5% for dyspepsia, and
0.3% for nausea. Overall, discontinuation from the drug
because of adverse GI side effects as compared to placebo
was about 2%. Because all BAS are not absorbed, systemic
side effects do not occur. However, because colesevelam
may affect absorption of certain drugs, it should not be
administered within 4 h of taking glyburide, levothyroxine,
and oral contraceptives containing ethinyl estradiol and
norethindrone and phenytoin. Colesevelam is also indicated
for the treatment of type 2 diabetes and reduces HBA1c by
about 0.5% and fasting blood sugars by about 14%.
Therefore, it is an ideal drug for diabetic patients who
require add-on therapy for getting LDL to goal. The
mechanism for this improvement is not well understood
but has been reviewed [9].
Combination Therapy with Colesevelam and Statins
As described, when BAS are given, the liver repletes its
stores of cholesterol by increasing synthesis and upregulat-
ing LDL receptors. However, if statins are given in
combination with BAS, increased cholesterol synthesis
cannot occur and only up-regulation of LDL receptors is
available to the liver to increase its stores of cholesterol. In
that situation, the cholesterol-lowering effect of each drug is
magnified. In a pooled analysis of three trials that analyzed
the effects of adding colesevelam to simvastatin, pravasta-
tin, or atorvastatin, the additional LDL lowering was 9.2%
[10]. Unfortunately, no outcome data are available to
compare high-dose statins and their effect on reducing
cardiovascular events versus low-dose statins plus colese-
velam. Because the beneficial effects of statins are thought
to be partly related to their pleiotropic effects, it is possible
that equal reduction in cholesterol by combination therapy
with low-dose statin plus colesevelam versus high doses of
statins alone might not translate into similar reduction in
cardiovascular morbidity. It is noteworthy, however, that in
the pooled data described above, further lowering of the
cholesterol with the addition of colesevelam to statins did
result in further lowering of CRP levels, which is a marker
of future cardiovascular events. There are also no studies
that compare overall tolerability of high-dose statins with
low-dose statins plus colesevelam, but in practice, when
myalgias increase creatine kinase or abnormal liver func-
tion tests preclude giving higher doses of statins, this
approach usually works well. There are also no studies that
have systematically looked at the addition of colesevelam
to high doses of statin in terms of tolerability, outcome data,
or quantified the additional LDL lowering that could be
expected. In practice, however, any type of combination
therapy that achieves recommended LDL goals in a way
that is tolerable, achieves long-term compliance, and can be
monitored for safety seems reasonable and practical.
Ezetimibe
Ezetimibe, like BAS, blocks the exogenous pathway of
cholesterol metabolism and lowers LDL to a similar degree
as colesevelam. Ezetimibe, in a dose of 10 mg, lowers LDL
by about 18% [11] and recent studies have shown similar
results with 5 mg compared with 10 mg in a double-blinded
study [12]. However, BAS reduces cholesterol available to
the liver by preventing enterohepatic absorption of the
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is rapidly absorbed, with peak concentrations occurring
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metabolized in the liver (>80%) to the pharmacologically
active ezetimibe glucuronide followed by enterohepatic
recycling and slow elimination. Ezetimibe glucuronide is
then excreted into the gut, localizes at the brush border of
the small intestine, and inhibits the absorption of ingested
cholesterol by about 50% [13]. Because ezetimibe is
systemically absorbed, this difference has implications as
to the safety of administering the drug during pregnancy, to
children, and to nursing mothers, as opposed to BAS,
which are not absorbed systemically.
Because ezetimibe and bile acid sequestrants work by
reducing intestinal absorption of cholesterol by different
mechanisms, their effects are additive and in several studies
the combination of the two were safe and further reduced
LDL by an additional 10% to 20% compared to either drug
alone [14]. Similarly, combining ezetimibe with statins
further reduces LDL. In one study, a strategy of doubling
the dose of rosuvastatin was compared to adding 10 mg of
ezetimibe to the same statin dose. When ezetimibe was
added to either 5 or 10 mg of rosuvastatin, there was about
a 21% further reduction in LDL as opposed to only a 6%
further reduction when the statin dose was doubled [15].
One study evaluated the effects of adding colesevelam to
patients with familial hypercholesterolemia already on
high-dose statins plus ezetimibe and found that the addition
of colesevelam reduced the LDL by another 18% (−11.8%
to −25%) with no safety issues [16]. Thus, the combination
of a potent statin, ezetimibe, and colesevelam has the
potential to decrease the LDL by as much as 75% to 80%
from baseline depending on the statin used. As with all
studies evaluating BAS, GI side effects were more common
in the colesevelam group as compared to placebo.
It would appear, however, based on the ARBITER 6-
HALTS trial, that patients whose LDL is below 100 mg/
dL and require the addition of a second drug to reach
their LDL goal should receive niacin rather than
ezetimibe. In that trial, patients with CAD or CAD
equivalents already on statins whose LDL was below
100 mg/dL were randomized to receive either niacin
extended-release (ER) 2,000 mg/d or ezetimibe 10 mg/d
[17]. The baseline LDL in each group was about 80 mg/dL
and the on-treatment LDL was about 66 mg/dL in the
ezetimibe group and about 71 mg/dL in the niacin-treated
group. However, only the niacin group demonstrated
regression of vascular disease as determined by measure-
ment of carotid intima-media thickness (CIMT) [17].
In clinical practice, however, the LDL levels that need to
be treated are usually much higher than those in the
ARBITER 6-HALTS trial and every study that has been
done with any method to lower LDL, such as statins [18],
BAS [7], and illeal bypass [19] have all shown a log-linear
relationship between LDL lowering and a reduction in CV
events regardless of the method used. There seems nothing
unusual about ezetimibe that would suggest that lowering
LDL with it in patients who cannot otherwise achieve their
LDL goal with statins would not benefit. In fact, a
reduction in C-reactive protein (CRP) levels, a marker of
risk, has been noted with ezetimibe alone and when added
to statin therapy, just as they have been reduced with BAS
[20] as well as with statins. In summary, within the usual
range of LDL levels being treated, ezetimibe is a very
reasonable option.
Strategies That Affect Endogenous Cholesterol
Metabolism
Niacin
Niacin is the best agent to raise HDL cholesterol. It also
increases LDL particle size and lowers lipoprotein(a) (Lp
(a)), all of which are thought to have vasculoprotective
effects [21]. However, niacin is also effective in lowering
total and LDL cholesterol. The effect appears to be dose
responsive and lowers total cholesterol by about 5%
(1,000 mg), 10% (2,000 mg), and 16% (3,000 mg) and
LDL 9% (1,000 mg), 17% (2,000 mg), and 21% (300 mg)
[22]. The combination of niacin with statins is additive. In
one study, 40 mg of lovastatin decreased LDL by 32%,
niacin ER at a dose of 2,000 mg reduced LDL by 14%, and
the combination decreased LDL by 42% [23].
Niacin appears to reduce total and LDL cholesterol by
several mechanisms [24]. First, the liver does not directly
produce LDL. It does produce VLDL, which is then
metabolized to intermediate-density lipoproteins (IDL) and
then into LDL. Niacin reduces the quantity of VLDL
produced in the liver in the following way. Two of the
major components of VLDL are triglycerides (TG) and
apoB, which are both produced in the liver. The initial
substrates for TG synthesis are glycerol and free fatty acids.
Niacin produces a large and rapid decrease in the release of
free fatty acids from adipose tissue, thus making them
unavailable to produce triglycerides in the liver. In addition,
niacin also directly inhibits the hepatocyte microsomal
diacylglycerol acyltransferase-2 (DGAT2), which is the key
enzyme that catalyzes the transformation of diacyl glycerol
to triglycerides. When TG synthesis is reduced, less is
available to lipidate apoB, which in turn results in
intrahepatic degradation of apoB as opposed to secretion.
The overall result of all this is to make less VLDL available
to produce LDL. Secondly, besides decreasing the quantity
of VLDL produced, niacin also decreases the size of the
VLDL particle. When triglyceride levels are high, large,
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cholesterol-ester transfer protein (CETP) exchanges TG in
the largest VLDL particles for cholesterol esters in the large
LDL particles. The acquired excess triglycerides in the
large LDL particles undergo rapid hydrolysis by hepatic
lipase, which leads to the formation of small dense LDL
particles, which have less affinity for hepatic LDL
receptors, which prolongs their presence in the circulation.
Thus, overall reduced production of LDL and increased
clearance of LDL by niacin reduces LDL and total
cholesterol levels.
Fibrates
The action of fibrates on the lipid profile is similar to niacin
in many ways, including a reduction in triglyceride levels,
an increase in HDL levels, and a shift of the LDL particle
size to a larger, less atherogenic type. However, they do so
by a different mechanism of action than niacin [25]. They
activate PPARα nuclear hormone receptors, leading to the
induction of lipoprotein lipase (LPL) expression and a
repression of the apoC-III gene at the transcriptional level.
This leads to increased oxidative metabolism of free fatty
acids in the liver, thus leading to decreased VLDL
production. There is also enhanced LPL-mediated catabo-
lism of VLDL because apoC-III on the VLDL particle
makes them less susceptible to the action of LPL. It is this
difference in mechanism of action that probably makes their
LDL lowering effect much less than niacin. Most studies
have seen only a 5% reduction in LDL, with no additive
benefit to statins, and a paradoxical increase in LDL in
patients with high baseline triglyceride levels of up to 14%
to 45% [26, 27]. Therefore, fibrates as an agent to
specifically lower total cholesterol and LDL appear to have
limited use, although their other benefits are important.
Red Yeast Rice
Red yeast rice has been used as a Chinese cuisine and
medicinal agent since the Ming dynasty of 1368 to 1644. It
contains isoflavanes that have antioxidant properties,
sterols, a group of compounds that are known to block
cholesterol absorption in the gut, and polyketides [28].
Polyketides are secondary metabolites from bacteria, fungi,
plants, and animals. Macrolide antibiotics, amphotericin,
and tetracycline are all derived from polyketides [29].
Monacolin K, which is lovastatin, is a polyketide found in
red yeast rice along with eight other monoclonins, all of
which probably reduce cholesterol synthesis in the liver.
They do so by reversible competitive inhibition of HMG-
CoA reductase, the enzyme that catalyzes the conversion of
HMG-CoA to mevalonate. Mevalonate is a required
building block for cholesterol biosynthesis. Isolated mon-
acolin K, lovastatin, and synthetically produced statins are
widely accepted as the agent of choice to reduce serum
cholesterol levels because of their predictability, safety, and
outcome data. Although myalgias are a significant obstacle
to using them, many options have been suggested that may
increase their tolerability. These include supplementation
with vitamin D [30], coenzyme Q10 [31], use of small
doses of rosuvastatin given twice weekly [32], or the use of
fluvastatin in the XL formulation [33]. However, there are
significant numbers of patients that cannot take any dose of
a statin because of myalgias. Some data suggest that when
any dose of a statin cannot be tolerated, red yeast rice may
be an alternative. In a study by Heber et al. [34], 83 patients
on a step 1 AHA diet were randomized to receive placebo
or 2.4 g of red yeast rice daily and followed for 12 weeks.
Compared with placebo, total cholesterol was reduced by
about 18% and LDL by 23%. There was no liver toxicity or
myalgia in either group [34]. In a study by Becker et al.
[35], 62 patients with a history of discontinuation of statins
due to myalgias were randomized to receive 1,800 mg of
red yeast rice or placebo for 12 weeks. The mean reduction
in LDL at 24 weeks was 21% and for TC was 16%. One
patient in the placebo group and two in the red yeast rice
group developed intolerable myalgias, none of whom had
an increase in CK levels, and no patients developed
evidence of liver toxicity [35]. The amount of lovastatin
in the red yeast rice group in both studies was only 5 to
7 mg and cannot explain the significant drop in cholesterol.
It is hypothesized that it is the combination of all the
monaclonins and other compounds in the red yeast rice that
may explain the significant cholesterol reductions seen.
Although these trials are relatively small, in 2006 Liu et al.
[36] performed a meta-analysis of 93 double-blind random-
ized trials using red yeast rice and found similar degrees of
cholesterol lowering. To determine if red yeast rice can
reduce cardiovascular events, a large, double-blind, ran-
domized prospective study was performed in 5,000 patients
post-myocardial infarction (MI) who were randomized to
receive red yeast rice or placebo and followed for an
average of 4.5 years. Total cholesterol levels declined by
13% from baseline and LDL by 20%. Adverse effects were
reported to be similar to placebo, but specific details were
not given. The reduction in total CVevents (nonfatal MI or
a cardiac death from any cause) was striking, with a 45%
reduction in major coronary events, 62% reduction in the
occurrence of nonfatal MI, and 32% reduction in fatal
coronary events [37].
A significant problem with recommending over-the-
counter red yeast rice products to patients is that there is
no standardization among marketed products. In one study
that analyzed the amount of monaclonin in 12 commercial-
ly available products, there was marked variability, with
total monaclonins varying from 0.31 to 11.15 mg/capsule,
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[38]. Because of this, we have chosen to make available to
our patients the two RYR compounds that are commercially
available and used in the Heber and Becker studies, both of
which were analyzed for monaclonin content and were
found to be effective. We have obtained very consistent
results by doing so and they have been well tolerated.
In summary, we believe that red yeast rice should be
used only as a last resort when statins can absolutely not be
tolerated. However, in those circumstances, there are much
data to support its use if commercially available regimens
that have been well analyzed are made available to patients.
Adding Nutrients and Fiber to the Diet
Dietary fiber is a collective term for a variety of plant
substances that are resistant to digestion in humans. There are
two types: water soluble and insoluble. Water-soluble fiber,
suchasoats,psyllium,pectin,andguargum,havebeenshown
to cause some reduction in total and LDL cholesterol, but the
degree to which they lower cholesterol has been quite varied.
Mechanisms ofactionproposedfor thiseffecthaveincluded a
bile acid binding effect similar to bile acid sequestrants, a
dietary cholesterol binding effect, inhibition of hepatic fatty
acid synthesis byproducts of fermentation, and increased
satiety leading to decreased caloric intake. In a meta-analysis
of 67 controlled trials by Brown et al. [39], it was concluded
that all the various soluble fibers reduce total cholesterol and
LDL by similar and small amounts within the practical range
of possible intake, the dose response being about a 5-mg/dL
reduction in total and LDL cholesterol for 3 g of soluble
fiber. This would be the equivalent of 1.5 servings of a
commercially available fiber supplement or three servings of
oatmeal per day.
Plant Stanols and Sterols
Plant stanols added to the diet have consistently shown a
reduction in LDL cholesterol. Because phytosterols are
structurally similar to cholesterol, they compete with choles-
terol for absorption in the digestive system when they are
consumed. A meta-analysis of 41 trials showed that the intake
of 2 g of stanols or sterols reduced LDL by about 10% but
higher doses added little. They do not affect the absorption of
fat-soluble vitamins A, D, E, and K [40]. The effects are
additive to statins but are not additive to bile acid
sequestrants nor to ezetimibe [41, 42]. They are commer-
cially available in many forms that should suit most patients’
preferences. These include chewable tablets (0.7 g per tablet)
orange juice, spreads, cheeses, soymilk, rice milk, and breads
(all fortified with plant sterols or stanols). A search on the
internet using “dietary supplements with plant stanols” will
be quite useful for finding all of these.
Soy Protein
Adding soy protein to the diet appears to result in some
reduction in total and LDL cholesterol. In a meta-analysis
of studies that substituted soy protein for animal protein,
the LDL-lowering effect ranged from 7% in the quartile
with the lowest cholesterol (127–197 mg/dL) and up to
24% in the group with the highest cholesterol (>355 mg/
dL) [43]. Studies have also shown that by simply adding
soy protein to patients’ regular diets can lower LDL levels
by 4% and in patients with the highest baseline levels by
8% [44]. Much has been debated as to the benefit of
alcohol-extracted soy protein, which is devoid of isofla-
vones, versus non-alcohol-extracted soy protein, but the
results are mixed. Overall, it appears that the combination
of soy protein with isoflavanes works best and this is the
recommendation of the American Heart Association, which
suggests that the addition of 25 to 50 g of soy protein will
decrease the LDL from 4% to 8% depending on the
baseline LDL level. No clear explanation as to the
mechanism of action of soy protein has emerged, though
many theories have been proposed [45]. A search on the
internet for sources of soy protein is very helpful. As an
example, one soy burger with a cup of soy milk and one-
half cup of edamame will yield about 30 g of soy protein.
Almonds
Almonds and other nuts have been demonstrated to
significantly reduce LDL in a dose-dependent manner,
and a number of epidemiologic trials have demonstrated a
reduction in cardiovascular risk. Their benefits may be
related to their high content of polyunsaturated/saturated
fatty acids (PUFA/SFA), nut protein, plant sterols, fiber, and
in addition they are the best natural source of vitamin E and
arginine, a precursor of nitric oxide [46]. In a small,
randomized crossover study, 27 men and women consumed
three isoenergetic diets. One group ate no almonds; one
group 36 g/d of almonds, and the third group 73 g/d of
almonds (for reference, one-quarter cup of almonds equals
about 70 g, which contains about 205 cal). This resulted in
a 4.4% and 9.4% reduction in LDL for the low-dose and
high-dose almond groups compared to the non-almond
consuming group. In the group that received no almonds or
half almonds, muffins were substituted to provide equal
amounts of fiber, protein, and SFA and PUFA as in the
almond groups [47].
Dietary Portfolio
As we have seen, plant stanols, dietary fiber, soy protein,
and almonds all cause mild reductions in cholesterol by
different mechanisms. A low-fat, low-cholesterol diet, with
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portfolio diet. In one study, hypercholesterolmic patients
were randomized to receive either a diet very low in
saturated fats (controls), the same diet plus lovastatin
20 mg, or a portfolio diet high in viscous fiber (9.8 g/
1,000 kcal), plant stanols (1 g/1,000 kcal), soy protein
(21.4 g/1,000 kcal), and almonds (14 g/1,000 kcal). The
LDL reduction in the control group was 8%, in the
lovastatin group 30.9%, and in the portfolio diet group
28.6%. The difference in LDL cholesterol between the
portfolio diet group and lovastatin group was not statisti-
cally significant. In addition, only a minimal fall in CRP of
10% was seen in the control group, but in the portfolio
group and the lovastatin group the reduction was about
30%, with no statistically significant difference between the
two groups [48].
Conclusions
Many patients who are at risk for coronary disease present
treatment challenges with regards to achieving their LDL
goal. This article reviewed numerous proven and well
tolerated options that are available to help each patient
reach their LDL goal and help prevent future cardiovascular
events. It also reviewed the mechanism of each and
demonstrated which combinations are effective and
rational, thus allowing physicians to reach success at
achieving LDL goals in a wide group of patients.
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